Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP9 | P14780 | 7/20 | 0.45 |
| ▸ | MMP8 | P22894 | 7/20 | 0.45 |
| ▸ | MMP2 | P08253 | 6/20 | 0.45 |
| ▸ | MMP1 | P03956 | 9/20 | 0.43 |
| ▸ | CTSD | P07339 | 1/20 | 0.41 |
| ▸ | FCER2 | P06734 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.40 |
| ▸ | LCK | P06239 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5557632 | 0.91 | MMP9 (0.46) | MMP9MMP8MMP2MMP1CTSD | |
| SCHEMBL5556455 | 0.88 | CTSB (0.47) | MMP9MMP8MMP2MMP1CTSD | |
| SCHEMBL5556660 | 0.82 | MMP2 (0.50) | MMP9MMP8MMP2MMP1FCER2 | |
| SCHEMBL5558595 | 0.79 | MMP9 (0.59) | MMP9MMP8MMP2MMP1FCER2 | |
| SCHEMBL5557789 | 0.78 | CTSB (0.40) | MMP9MMP8MMP2CTSDLCK | |
| SCHEMBL5556810 | 0.77 | ALDH1A1 (0.46) | — | |
| SCHEMBL5552416 | 0.77 | ALDH1A1 (0.46) | — | |
| SCHEMBL5552367 | 0.76 | MMP2 (0.46) | MMP9MMP8MMP2MMP1FCER2 | |
| SCHEMBL5556812 | 0.75 | MMP3 (0.39) | MMP9MMP8MMP2MMP1PTPN1 | |
| SCHEMBL5552925 | 0.75 | MMP3 (0.47) | MMP9MMP2MMP1PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070197577-A1 | Inhibitors of anthrax lethal factor | CENGENT THERAPEUTICS (US) | 2007-08-23 | — | — | US | disclosed |
| WO-2005027856-A2 | INHIBITORS OF ANTHRAX LETHAL FACTOR | CENGENT THERAPEUTICS (US) | 2005-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197577-A1 | Inhibitors of anthrax lethal factor | APAF1, ANTXR2, LITAF | MMP9 182/4885MMP8 24/4885MMP2 85/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.